
Male contraception just had its biggest financial vote of confidence yet. In June 2026, Contraline — a clinical-stage biopharmaceutical company — closed a $92.5 million Series B round, one of the largest venture rounds ever raised for a male birth control product, to push its once-daily contraceptive gel, NES/T, toward a Phase 3 trial. At the same time, more than 20,000 men have already signed up for future trials of the company’s pipeline, and new data presented this year at the American Urological Association’s 2026 annual meeting showed the hormone combination suppressing sperm production in the large majority of men who used it. None of this means a product is sitting on pharmacy shelves yet — but after decades of false starts, the pieces are now lining up in a way they haven’t before.
What NES/T actually is
NES/T is a topical, reversible gel applied daily to the shoulders and upper arms. It combines segesterone acetate — known as Nestorone, a synthetic progestin — with testosterone. The progestin suppresses the brain’s hormonal signals to the testicles, which lowers sperm production to contraceptive levels. The testosterone is included specifically to offset that suppression, keeping libido, mood, erectile function, and muscle mass within a normal range. The compound itself isn’t new: it was originally developed by the Population Council, a nonprofit reproductive health research organization, in partnership with the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development. Contraline now holds the exclusive worldwide license to commercialize it.
Why investors suddenly care
The $92.5 million round was co-led by BVF Partners and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, and Invus. “Male contraception represents one of the largest unmet needs in reproductive health,” Contraline CEO Kevin Eisenfrats said of the raise. RA Capital partner Laura Stoppel put it more bluntly, calling male contraception “an overlooked area” that’s finally attracting serious capital. The money is earmarked specifically to fund NES/T’s move into late-stage development. Contraline is also developing ADAM, a separate long-acting, non-hormonal, reversible contraceptive, in earlier-stage clinical testing — meaning the company is now running two distinct approaches to the same problem in parallel.
What the trial data actually shows
NES/T has already completed a Phase 2b trial enrolling 462 couples at sites around the world, with results described as encouraging on efficacy, tolerability, reversibility, and user acceptability — though full published results are still pending. Separately, at AUA 2026 in Washington, D.C., Baylor College of Medicine urology professor Dr. Mohit Khera presented data showing that adding the progestin to a testosterone-only gel brought sperm counts down to contraceptive thresholds in a large majority of men, compared with only a small fraction when testosterone was used alone — and most men who responded did so within a few months of starting. Reversibility data specific to the gel isn’t published yet, but pooled results from earlier injectable and implant-based hormonal contraceptives for men found that most participants recovered normal sperm counts within a year, and nearly all did within two years of stopping. That history isn’t spotless: an injectable hormonal trial roughly a decade ago was halted early by an independent safety monitoring board after participants reported mood-related side effects, a cautionary data point researchers say they’re watching closely this time around.
The demand is already there
Surveys back up what the sign-up numbers suggest. In an international survey conducted in 2021-2022, 61% of men said they’d be open to trying a new male contraceptive; in the U.S., that figure was lower at 39%, but climbed to 49% in a 2023 follow-up taken after the Dobbs decision reshaped the national conversation around reproductive responsibility. Separate survey data cited by Contraline suggests more than 40 million men in the U.S. alone would consider a novel contraceptive option if one were available. Part of the appeal is simply the state of the alternatives: condoms, the only widely available method that puts contraceptive control in men’s hands today, carry a real-world user failure rate of up to 16% — a number that helps explain why Contraline says it has more than 20,000 volunteers registered for future studies, even though its next research phase for the ADAM candidate only needs 200 to 300 participants.
What’s still uncertain
None of this puts NES/T on pharmacy shelves soon. Phase 3 — the large, final-stage trial regulators require before approval — isn’t expected to begin until 2027, and Phase 3 programs for contraceptives typically run for several years given how long researchers need to track real-world pregnancy prevention and reversibility. Industry voices interviewed by health reporters this year have floated the “end of the decade” as an optimistic window for commercial availability in the U.S., with the caveat that approval in one country doesn’t fast-track approval elsewhere — regulatory review in other markets can lag by years. Long-term, gel-specific reversibility data also still doesn’t exist; everything to date is extrapolated from older hormonal methods. Whether NES/T clears Phase 3 without repeating the mood-related issues that derailed earlier hormonal trials is the question that will ultimately decide whether this becomes the first pharmacologic contraceptive ever approved for men.
The bottom line
For the first time in a long history of stalled male contraceptive research, the ingredients for real progress are present at once: a well-funded company, published mid-stage data, a packed volunteer pipeline, and a regulatory pathway with an actual target year attached. It’s still a multi-year wait, and hormonal male contraception has broken promises before. But NES/T is closer to a pharmacy shelf than any male birth control candidate has been in decades — and the next milestone to watch for is simple: whether Phase 3 actually starts on schedule in 2027.
As an Amazon Associate, TrendScope Daily earns from qualifying purchases made through links in this article.